Podcast

Handing a Piece of Life Back

Author(s):

Kristie L. Kahl

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

After her oncologist recommended she us a diagnostic test, called the Oncotype DX assay, that helps make informed, individualized treatment decisions, Laurie was able to forgo chemotherapy treatment when she received a recurrence score that indicated that she had a relatively low risk of her cancer returning.

This week, we spoke with Laurie about her treatment decisions, and how this diagnostic test gave her what she calls “a piece of her life back.”

Related Videos
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with a brown hair tied into a bun.
Related Content
Karen Cohn is a retired middle school special education teacher who was diagnosed with follicular lymphoma in July 2020. Catch up on all of Karen's blogs here!
March 31st 2025

The Positivity Trap of Follicular Lymphoma and Cancer

Karen Cohn
As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
FDA grants fast track designation to azer-cel in relapsed/refractory DLBCL: © stock.adobe.com
March 21st 2025

FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset

Spencer Feldman
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of blood cells.
March 17th 2025

Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia

Ryan Scott
Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.
Felicia Mitchell is a survivor of stage 2b HER2-positive breast cancer diagnosed in 2010. Catch up on all of Felicia's blogs here!
March 17th 2025

A Picture is Worth Ten Thousand Words When it Comes to Cancer

Felicia Mitchell
Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.